“A combo of Bristol Myers’ LAG-3 inhibitor relatlimab and PD-1 blocker Opdivo posted a progression-free survival of 10.12 months in patients with metastatic or unresectable melanoma compared with 4.63 months for patients on Opdivo alone, according to data from the Phase II/III RELATIVITY-047 study set to be presented at ASCO in June.”
“On top of adding a novel molecule into the fold, an approval would crack open a whole new world of combo potential for Opdivo, Bristol Myers’ third-bestselling drug and a clear No. 2 in terms of PD-1 sales behind Merck’s behemoth Keytruda. Opdivo cleared $1.72 billion in sales in Q1.”
https://endpts.com/asco21-bristol-m...udy-for-lag-3-pathway-setting-up-a-us-filing/
“A combo of Bristol Myers’ LAG-3 inhibitor relatlimab and PD-1...
-
- There are more pages in this discussion • 3,072 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.010(0.88%) |
Mkt cap ! $199.8M | |||
| Open | High | Low | Value | Volume |
| $1.19 | $1.19 | $1.15 | $34.12K | 29.39K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 8731 | 3 |
View Market Depth
| Last trade - 10.37am 23/07/2025 (20 minute delay) ? |
| RAC (ASX) Chart |